Thalidomide-4-NH-PEG2-COO(t-Bu)
Thalidomide-4-NH-PEG2-COO(t-Bu) is a versatile E3 ligase ligand featuring a thalidomide core, optimized for PROTAC drug development and molecular glue applications. This compound incorporates a PEG2 linker and a protected carboxylic acid (tert-butyl ester) at the 4-amino position, enabling flexible conjugation strategies for targeted protein degradation. Specifically designed for generating cereblon (CRBN)-recruiting PROTAC molecules, Thalidomide-4-NH-PEG2-COO(t-Bu) facilitates the design of heterobifunctional degraders aimed at a wide range of protein targets and supports research on next-generation therapeutic modalities.
Structure of 2140807-16-3
Assurance
Delivery
Support
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
- Comprehensive PROTAC Platform
- Scientific Expertise & Technical Support
- Custom Synthesis & Design Service
- Extensive Product Coverage
- Cutting-Edge Innovation
- Fast Delivery & Global Support
- 24/7 customer service
- 100% quality assurance
Popular Publications Citing BOC Sciences Products
Background Introduction
Thalidomide derivatives have emerged as cornerstone ligands for recruiting the Cereblon (CRBN) E3 ubiquitin ligase complex in the rapidly expanding field of targeted protein degradation. Thalidomide-4-NH-PEG2-COO(t-Bu) is a strategically designed thalidomide analog featuring a PEG2 (ethylene glycol) linker at the 4-amino position with a tert-butyl-protected carboxyl group. This structure provides superior water solubility and flexible chemical reactivity, enabling scientists to efficiently build next-generation PROTACs and molecular glue degraders for research and therapeutic applications.
Mechanism
Thalidomide-4-NH-PEG2-COO(t-Bu) functions by specifically binding to the CRBN substrate receptor within the CUL4A-CRBN E3 ubiquitin ligase complex. Through this high-affinity interaction, it serves as a recruitment handle for CRBN upon conjugation to a ligand for the protein of interest, enabling the targeted ubiquitination and proteasomal degradation of disease-related proteins. The PEG2 spacer improves linker flexibility and membrane permeability, while the tert-butyl-protected carboxyl group allows for facile, orthogonal conjugation during PROTAC assembly.
Applications
Thalidomide-4-NH-PEG2-COO(t-Bu) is an ideal building block for the synthesis of CRBN-based PROTACs, molecular glues, and other targeted protein degradation tools. Its enhanced solubility and functional versatility make it highly valuable for drug discovery, hit-to-lead development, and protein function studies in both academic and pharmaceutical research settings. Main applications include:
• Construction of CRBN E3 ligase ligand modules for PROTAC synthesis• Development of modular protein degraders with improved drug-like properties
• Structure-activity relationship (SAR) optimization in degrader design
• Chemical biology and target identification studies
• Custom synthesis for medicinal chemistry and early-stage drug development
• Consistent batch-to-batch reproducibility with complete QC documentation
• Supplied with COA, MSDS, and analytical data for traceability
• Reliable global shipping with stability-guaranteed packaging
• Dedicated technical support and optional custom synthesis service
• Demonstrates strong binding affinity to CRBN, VHL, or other E3 ligases
• Enables stable E3 ligase recruitment for targeted protein degradation
• Polyethylene glycol (PEG2) linker enhances aqueous solubility and biocompatibility.
• Perfect for constructing CRBN-recruiting PROTACs with customizable conjugation flexibility.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Related Product Recommendations
Please contact us with any specific requirements and we will get back to you as soon as possible.





